Hemostemix Announces Trademark Granted by Switzerland and Interest Payment

About this update from Hemostemix Inc

[{"type":"text","content":"Hemostemix Announces Trademark Granted by Switzerland and Interest PaymentCalgary, Alberta--(Newsfile Corp. - June 11, 2024) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce it was notified by the World Intellectual Property Organization that it was granted the trademark Your Fountain of Youth by the Swiss Trademark Office. \"In four heart and three chronic limb threatening ischemia (CLTI) trials, including one retrospective study of 54 patients, ACP-01 is demonstrated to be safe and statistically efficacious as a treatment of no-option cardiovascular disease,\" stated Thomas Smeenk, CEO. \"In layman's terms, ACP is the cardiovascular patient's fountain of youth,\" Smeenk said.For example, published in Stem Cell Research & Therapy, November 2023, the mean improvement in the volume of blood ejected with each heartbeat was 27% (p<0.003), comparing the pre-procedure LVEF% of all the patients with the final follow-up at 12 months. In its Phase II clinical trial, as published in the J Biomed Res Environ Sci, February 2024, ulcer size in the treated group decreased significantly (p = 0.01) by 3 months, as compared to placebo group, (p < 0.54). Moreover, the rate of amputation (4.8%) and death (4.8%) in the treated subgroup was substantially less than the placebo group which exhibited an amputation rate of 25% and 1 death (12.5%).Saving a limb is saving a life. Whereas the five year mortality rate of patients suffering from CLTI is 60%. ACP increased the survival rate of patients in the Phase II clinical trial followed by the University of Toronto and University of British Columbia, who published that 83% of patients followed for up to 4.5 years experienced healing of ulcers, resolution of pain, and no major amputation. In accordance with the debenture agreement, Hemostemix will make the 2023 interest payment of $226,688.25 to the holders of the $2.75 million Convertible Debenture with 2,229,616 shares, priced at $0.101671 per share (\"shares-for-interest\"), equating to approximately $8,243.20 of interest paid with approximately 8102.77 shares per $1,000 debenture. The shares-for-interest are subject to all necessary regulatory approvals including acceptance from the Exchange. All securities issued under the shares-for-interest will be subject to a four-month hold period from the closing date u...

More updates from Hemostemix Inc